FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060323461> ?p ?o ?g. }

• W2060323461 abstract "BACKGROUND: Predictive factors of survival benefit from taxane over non-taxane based adjuvant chemotherapy regimens are needed. Recent studies have suggested that “intrinsic” breast cancer subtypes may differ in their responsiveness to specific chemotherapeutics. Tumor samples from GEICAM 9906 study (Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone [FEC] or FEC Followed by Paclitaxel [FEC-P] for Early Breast Cancer, JNCI 100:805, 2008) were gene expression profiled using the RT-qPCR PAM50 clinical test in order to identify potential predictive markers of taxane clinical benefit. METHODS: 793 formalin-fixed paraffin-embedded tumors were studied and classified into intrinsic subtypes (Luminal A & B, HER2−enriched, Basal-like, and Normal) using the PAM50 test. The assay also provided gene expression scores for the standard protein biomarkers usually measured by immunohistochemistry (ESR1/ER, PGR/PR, and ERBB2/HER2) and a meta-gene score for proliferation (proliferation signature) and for a luminal gene signature. Intrinsic subtypes, individual genes, or meta-genes were correlated with disease-free survival (DFS). Multivariable Cox regression analyses were performed to determine the significance of the interaction between treatment and intrinsic subtypes, single genes and meta-genes, adjusting for standard clinicopathological factors. RESULTS: A 8.7 years follow-up update of GEICAM 9906 trial confirmed a statistically significant advantage of FEC-P over FEC in terms of DFS (p=0.016) and OS (p=0.013). Exploratory analyses for prognostic factors showed that treatment arm (p=0.016), tumor size (p Concerning predictive factors, exploratory analyses were performed and interaction tests were calculated. Theses analyses showed that FEC-P was superior to FEC in low PGR expression (HR= 0.68, p=0.034) and not in high PGR group (HR=0.83, p=0.245); interaction test p=0.358. Similarly, FEC-P was superior in low ERBB2 expression (HR=0.67; p=0.005) and not in the high ERBB2 group (HR=0.92, P=0.707); interaction test p=0.256. Interestingly, superiority of FEC-P was observed for the low Proliferation Signature group (HR=0.58, p= 0.006) in contrast to the high proliferation group (HR=0.93, p=0.633); the interaction test showed an almost statistical significant difference (p=0.069). The FEC-P arm showed improved outcome in all genomic intrinsic subtypes, although no subtype alone reached statistical significance. CONCLUSION: Our study suggests that the PAM50 proliferation signature could be predictive of benefit for adding weekly paclitaxel to the adjuvant chemotherapy FEC regimen. These results need further validation in an independent study. The last two authors of this abstract have contributed equally to this study. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-06-04." @default.
• W2060323461 created "2016-06-24" @default.
• W2060323461 creator A5000810134 @default.
• W2060323461 creator A5006639549 @default.
• W2060323461 creator A5008504309 @default.
• W2060323461 creator A5017224474 @default.
• W2060323461 creator A5018612347 @default.
• W2060323461 creator A5019349196 @default.
• W2060323461 creator A5020308339 @default.
• W2060323461 creator A5020335557 @default.
• W2060323461 creator A5023639232 @default.
• W2060323461 creator A5026257794 @default.
• W2060323461 creator A5039927103 @default.
• W2060323461 creator A5040177206 @default.
• W2060323461 creator A5043702939 @default.
• W2060323461 creator A5045301167 @default.
• W2060323461 creator A5059577028 @default.
• W2060323461 creator A5061114358 @default.
• W2060323461 creator A5065957731 @default.
• W2060323461 creator A5069723692 @default.
• W2060323461 creator A5075937719 @default.
• W2060323461 creator A5078662022 @default.
• W2060323461 creator A5089644298 @default.
• W2060323461 date "2011-12-15" @default.
• W2060323461 modified "2023-09-26" @default.
• W2060323461 title "P1-06-04: PAM50 Proliferation Index Predicts Response to Weekly Adjuvant Paclitaxel in Node-Positive Operable Breast Cancer." @default.
• W2060323461 doi "https://doi.org/10.1158/0008-5472.sabcs11-p1-06-04" @default.
• W2060323461 hasPublicationYear "2011" @default.
• W2060323461 type Work @default.
• W2060323461 sameAs 2060323461 @default.
• W2060323461 citedByCount "2" @default.
• W2060323461 countsByYear W20603234612013 @default.
• W2060323461 countsByYear W20603234612019 @default.
• W2060323461 crossrefType "proceedings-article" @default.
• W2060323461 hasAuthorship W2060323461A5000810134 @default.
• W2060323461 hasAuthorship W2060323461A5006639549 @default.
• W2060323461 hasAuthorship W2060323461A5008504309 @default.
• W2060323461 hasAuthorship W2060323461A5017224474 @default.
• W2060323461 hasAuthorship W2060323461A5018612347 @default.
• W2060323461 hasAuthorship W2060323461A5019349196 @default.
• W2060323461 hasAuthorship W2060323461A5020308339 @default.
• W2060323461 hasAuthorship W2060323461A5020335557 @default.
• W2060323461 hasAuthorship W2060323461A5023639232 @default.
• W2060323461 hasAuthorship W2060323461A5026257794 @default.
• W2060323461 hasAuthorship W2060323461A5039927103 @default.
• W2060323461 hasAuthorship W2060323461A5040177206 @default.
• W2060323461 hasAuthorship W2060323461A5043702939 @default.
• W2060323461 hasAuthorship W2060323461A5045301167 @default.
• W2060323461 hasAuthorship W2060323461A5059577028 @default.
• W2060323461 hasAuthorship W2060323461A5061114358 @default.
• W2060323461 hasAuthorship W2060323461A5065957731 @default.
• W2060323461 hasAuthorship W2060323461A5069723692 @default.
• W2060323461 hasAuthorship W2060323461A5075937719 @default.
• W2060323461 hasAuthorship W2060323461A5078662022 @default.
• W2060323461 hasAuthorship W2060323461A5089644298 @default.
• W2060323461 hasConcept C121608353 @default.
• W2060323461 hasConcept C126322002 @default.
• W2060323461 hasConcept C143998085 @default.
• W2060323461 hasConcept C204232928 @default.
• W2060323461 hasConcept C2776802502 @default.
• W2060323461 hasConcept C2777292972 @default.
• W2060323461 hasConcept C2777511904 @default.
• W2060323461 hasConcept C2780835546 @default.
• W2060323461 hasConcept C2781190966 @default.
• W2060323461 hasConcept C530470458 @default.
• W2060323461 hasConcept C71924100 @default.
• W2060323461 hasConceptScore W2060323461C121608353 @default.
• W2060323461 hasConceptScore W2060323461C126322002 @default.
• W2060323461 hasConceptScore W2060323461C143998085 @default.
• W2060323461 hasConceptScore W2060323461C204232928 @default.
• W2060323461 hasConceptScore W2060323461C2776802502 @default.
• W2060323461 hasConceptScore W2060323461C2777292972 @default.
• W2060323461 hasConceptScore W2060323461C2777511904 @default.
• W2060323461 hasConceptScore W2060323461C2780835546 @default.
• W2060323461 hasConceptScore W2060323461C2781190966 @default.
• W2060323461 hasConceptScore W2060323461C530470458 @default.
• W2060323461 hasConceptScore W2060323461C71924100 @default.
• W2060323461 hasLocation W20603234611 @default.
• W2060323461 hasOpenAccess W2060323461 @default.
• W2060323461 hasPrimaryLocation W20603234611 @default.
• W2060323461 hasRelatedWork W2012732226 @default.
• W2060323461 hasRelatedWork W2017832231 @default.
• W2060323461 hasRelatedWork W2046335090 @default.
• W2060323461 hasRelatedWork W2095698687 @default.
• W2060323461 hasRelatedWork W2152300187 @default.
• W2060323461 hasRelatedWork W2313828687 @default.
• W2060323461 hasRelatedWork W2314610986 @default.
• W2060323461 hasRelatedWork W2319391127 @default.
• W2060323461 hasRelatedWork W2320380229 @default.
• W2060323461 hasRelatedWork W2325502715 @default.
• W2060323461 hasRelatedWork W2325582726 @default.
• W2060323461 hasRelatedWork W2330034879 @default.
• W2060323461 hasRelatedWork W2593713286 @default.
• W2060323461 hasRelatedWork W2739758397 @default.
• W2060323461 hasRelatedWork W2937788986 @default.
• W2060323461 hasRelatedWork W2942507864 @default.
• W2060323461 hasRelatedWork W2944166485 @default.
• W2060323461 hasRelatedWork W2999302466 @default.
• W2060323461 hasRelatedWork W3016755425 @default.
• W2060323461 hasRelatedWork W3100417091 @default.

• next